Overview

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

Status:
Completed

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the safety and efficacy of dosing with mipomersen for 26 weeks in treating severely hypercholesterolemic patients who are on a maximally tolerated lipid-lowering regimen and who are not on apheresis.

Phase:

Phase 3

Details

Lead Sponsor:

Kastle Therapeutics, LLC

Collaborator:

Ionis Pharmaceuticals, Inc.

Treatments:

Mipomersen